Abstract
Gastric cancer (GC) is the second most lethal cancer world-wide, and the poor overall 5-year survival rate of <25 % for GC is largely due to both the late detection of this aggressive disease and limited effectiveness of current treatment options. Collectively, these observations underscore the need to identify new molecular targets (i.e., genes) to serve as biomarkers for early detection and/or treatment strategies to improve patient outcomes. While GC represents a growing number of cancers whereby deregulation of the immune system is linked to tumor initiation and progression, the identity of innate immune regulators with oncogenic potential in the host gastric mucosal epithelium remains obscure.
Over the last couple of decades experimental mouse models for many cancer types have been widely used with great success to identify genes whose expression and/or mutation status influences tumorigenesis. Considering the recent mounting evidence for the role of innate immunity in the pathogenesis of inflammation-associated cancers such as GC, much attention has focused on members of the Toll-like receptor (TLR) family, which are key components of the innate immune system primarily known to trigger inflammatory responses upon pathogen detection. Here, we describe techniques used on genetic mouse models for GC to examine the role of specific TLR family members in the pathogenesis of GC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fox JG, Wang TC (2007) Inflammation, atrophy, and gastric cancer. J Clin Invest 117(1):60–69
Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175–1183
Correa P (1992) Human gastric carcinogenesis – a multistep and multifactorial process – 1st american-cancer-society award lecture on cancer-epidemiology and prevention. Cancer Res 52(24):6735–6740
Correa P, Piazuelo MB (2011) Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 7(1):59–64
Fuccio L, Zagari RM, Eusebi LH et al (2009) Meta-analysis: can helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151(2):121–128
Lee YC, Chen TH, Chiu HM et al (2013) The benefit of mass eradication of helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62(5):676–682
Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12(3):354–362
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 11(5):373–384
Uno K, Kato K, Atsumi T et al (2007) Toll-like receptor (tlr) 2 induced through tlr4 signaling initiated by helicobacter pylori cooperatively amplifies inos induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 293(5):G1004–G1012
Hold GL, Rabkin CS, Chow WH et al (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132(3):905–912
Tahara T, Arisawa T, Wang F et al (2007) Toll-like receptor 2–196 to 174del polymorphism influences the susceptibility of japanese people to gastric cancer. Cancer Sci 98(11):1790–1794
Zeng HM, Pan KF, Zhang Y et al (2011) Genetic variants of toll-like receptor 2 and 5, helicobacter pylori infection, and risk of gastric cancer and its precursors in a Chinese population. Cancer Epidemiol Biomarkers Prev 20(12):2594–2602
Tye H, Kennedy CL, Najdovska M et al (2012) Stat3-driven upregulation of tlr2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22(4):466–478
Mandell L, Moran AP, Cocchiarella A et al (2004) Intact gram-negative helicobacter pylori, helicobacter felis, and helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 72(11):6446–6454
Tebbutt NC, Giraud AS, Inglese M et al (2002) Reciprocal regulation of gastrointestinal homeostasis by shp2 and stat-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8(10):1089–1097
Jenkins BJ, Grail D, Nheu T et al (2005) Hyperactivation of stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes tgf-beta signaling. Nat Med 11(8):845–852
Kanda N, Seno H, Konda Y et al (2004) Stat3 is constitutively activated and supports cell survival in association with surviving expression in gastric cancer cells. Oncogene 23(28):4921–4929
Gong W, Wang L, Yao JC et al (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11(4):1386–1393
Yakata Y, Nakayama T, Yoshizaki A et al (2007) Expression of p-stat3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 30(2):437–442
McCormack W, Oshima M, Tan P et al (2012) Toll-like receptor 2: therapeutic target for gastric carcinogenesis. Oncotarget 3(11):1260–1261
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
West, A.C., Jenkins, B.J. (2016). Investigating the Role of Toll-Like Receptors in Mouse Models of Gastric Cancer. In: McCoy, C. (eds) Toll-Like Receptors. Methods in Molecular Biology, vol 1390. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3335-8_25
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3335-8_25
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3333-4
Online ISBN: 978-1-4939-3335-8
eBook Packages: Springer Protocols